Navigation Links
Virus-like particle vaccine protects monkeys from chikungunya virus
Date:1/28/2010

An experimental vaccine developed using non-infectious virus-like particles (VLP) has protected macaques and mice against chikungunya virus, a mosquito-borne pathogen that has infected millions of people in Africa and Asia and causes debilitating pain, researchers at the National Institutes of Health have found.

Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) developed the vaccine because there is no vaccine or treatment for chikungunya virus infection. Details about the vaccine were published today in the online version of Nature Medicine.

"Increases in global travel and trade, and possibly climate change, may be contributing to the spread of disease-carrying mosquitoes into new areas," says NIAID Director Anthony S. Fauci, M.D. "Finding safe and effective human vaccines for chikungunya virus and other insect-borne pathogens is an important global health priority."

To develop the vaccine, scientists in NIAID's Vaccine Research Center (VRC) identified the proteins that give rise to chikungunya VLPs. The VLPs mimic actual virus particles but cannot cause infection, so they can be used safely as a vaccine to elicit immune responses. The researchers immunized rhesus macaques with the VLPs, waited 15 weeks before exposing the animals to chikungunya virus, and observed that the vaccine provided complete protection from infection.

When the group found that antibodies were responsible for immune protection, they transferred antibody-containing serum from the vaccinated macaques to mice with deficient immune systems. The mice then were exposed to a lethal dose of chikungunya virus, but the immune serum protected them from infection.

"This virus-like particle vaccine provides a promising way to protect against an emerging infectious disease threat," says VRC Director Gary Nabel, M.D., Ph.D. "This same approach could possibly extend to viruses related to chikungunya that cause fatal diseases such as encephalitis." Dr. Nabel says his group plans to seek approval for clinical trials to further evaluate the safety and efficacy of the vaccine in humans.

There are two VLP vaccines for other diseases approved by the Food and Drug Administration: one for hepatitis B and one for human papillomavirus. This study marks the first time that scientists have used VLPs in a vaccine to protect against chikungunya virus, which is in the genus Alphavirus. The group plans to determine whether VLPs will work against other alphaviruses, such as Western and Eastern equine encephalitis virus found in the United States and o'nyong-nyong virus found in Africa.


'/>"/>

Contact: NIAID Office of Communications
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. New Pick-Up Filters Remove Particles at The Source
2. School classroom air may be more polluted with ultrafine particles than outdoor air
3. Behavior modification could ease concerns about nanoparticles
4. Particles Detected in Vials from Genzymes Plant Not Expected to Impact Aldurazyme or Naglazyme
5. Particle Beam Radiation Therapy Promising But Unproven for Treating Cancer
6. UCSB researchers develop drug delivery system using nanoparticles and lasers
7. Nanoparticle-delivered 'Suicide' Genes Slowed Ovarian Tumor Growth
8. AlphaRx Presents Positive Preclinical Data on Zysolin(TM) Inhalable Nanoparticles at Controlled Release Society Annual Meeting
9. Making nanoparticles in artificial cells
10. Particle Sciences Further Expands Combination Product Development Capabilities
11. UCF researchers nanoparticles could someday lead to end of chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Inflow IQ & Inflownomics ... serious so build on a solid foundation. As experts in dangerous situations the ... that is coming soon. Inflownomics deliver ripe, fresh, clean & refreshing knowledge systems that ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The American ... 2017 marks the 40th Anniversary of ABQAURP’s dedication to Health Care Quality and Management ... who have contributed not only to the association, but also to the Health Care ...
(Date:3/23/2017)... Jersey (PRWEB) , ... March 23, 2017 , ... ... of herbal-based and non-steroidal skincare products, was awarded as winners of American Dreams ... products. This competition was hosted jointly by HSN and Good Housekeeping. , ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... and the New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April ... , How will the new EU MDR language change the way manufacturers ...
(Date:3/23/2017)... ... March 23, 2017 , ... GeBBS Healthcare Solutions ... at HCCA’s 21st annual Compliance Institute on March 26-28 in National Harbor, Maryland. ... all medical chart types with a comprehensive set of features including built-in workflow, ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... de marzo de 2017   VWR ... soluciones de productos y servicios para clientes de ... adquirido EPL Archives, Inc., una organización de servicios ... todo el ciclo de vida de investigación de ... de archivo, almacenamiento de documentos y servicios complementarios. ...
(Date:3/22/2017)... 22, 2017 Ampio Pharmaceuticals, Inc. (NYSE ... Ampion™, a low molecular weight fraction of human ... it is re-issuing its previous release that was made ... that are required under the NYSE MKT Company ... additional disclosures along with the previously disclosed update ...
(Date:3/22/2017)... New Jersey,s hospitals ... and saved $641 million in healthcare costs between 2012 ... quality improvement program. The results reflect ... part of a national initiative from the U.S. Department ... Jersey Hospital Association and its affiliate, the Health Research ...
Breaking Medicine Technology: